Your browser doesn't support javascript.
loading
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.
Kwak, Soo Heon; Han, Kyung Ah; Kim, Kyung-Soo; Yu, Jae Myung; Kim, EunSook; Won, Jong Chul; Kang, Jun Goo; Chung, Choon Hee; Oh, Seungjoon; Choi, Sung Hee; Won, Kyu Chang; Kim, Sin Gon; Cho, Seung Ah; Cho, Bo Young; Park, Kyong Soo.
Afiliação
  • Kwak SH; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Han KA; Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University, Seoul, South Korea.
  • Kim KS; Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.
  • Yu JM; Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea.
  • Kim E; Department of Internal Medicine, Ulsan University Hospital, College of Medicine University of Ulsan, Ulsan, South Korea.
  • Won JC; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, South Korea.
  • Kang JG; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea.
  • Chung CH; Department of Internal Medicine, Wonju Severance Christian Hospital, Wonju, South Korea.
  • Oh S; Department of Internal Medicine, Kyung Hee University Hospital, Seoul, South Korea.
  • Choi SH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Won KC; Department of Internal Medicine, Yeungnam University Medical Center, Daegu, South Korea.
  • Kim SG; Department of Internal Medicine, Korea University Anam Hospital, Seoul, South Korea.
  • Cho SA; Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, Republic of Korea.
  • Cho BY; Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, Republic of Korea.
  • Park KS; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Diabetes Obes Metab ; 25(7): 1865-1873, 2023 07.
Article em En | MEDLINE | ID: mdl-36872067
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Clinical_trials Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Coréia do Sul
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Clinical_trials Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Coréia do Sul